ArticleInternational journal of MS care

Disability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta/Glatiramer Acetate Therapies: A NARCOMS Analysis.

Stacey S Cofield et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.